AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30336373 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 244
Study 30336373 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 244
Study 28823950 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive training (n = 40)
Number of subjects: 80
Study 28823950 — intervention group
Group type: COMPARATOR
Intervention: Negative training (n = 40)
Number of subjects: 80
Study 27129892 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity with diet-induced weight loss
Number of subjects: 11
Study 27129892 — intervention group
Group type: COMPARATOR
Intervention: Post-intervention subjects
Number of subjects: 11
Study 27129892 — intervention group
Group type: COMPARATOR
Intervention: Succinate dehydrogenase and fiber type
Number of subjects: 11
Study 25330671 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 133
Study 25330671 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Spinal‐Epidural Anesthesia (CSEA)
Number of subjects: 133
Study 25330671 — intervention group
Group type: COMPARATOR
Intervention: Epidural Anesthesia (EA)
Number of subjects: 133
Study 22632824 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (packaging materials stored for various intervals)
Number of subjects: 0
Study 22632824 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 20143328 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing‐Single (MI‐Single)
Number of subjects: 256
Study 20143328 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing‐Group (MI‐Group)
Number of subjects: 256
Study 20143328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐Led Hepatitis Health Promotion (HHP)
Number of subjects: 256
Study 20143328 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 256
Study 18824643 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25 to 50 mg/d)
Number of subjects: 6632
Study 18824643 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (placebo)
Number of subjects: 6632
Study 16078134 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic differential equations (SDEs) in population PK/PD modeling
Number of subjects: 0
Study 16078134 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Kalman Filter (EKF)
Number of subjects: 0
Study 12166709 — intervention group
Group type: EXPERIMENTAL
Intervention: Clasp-retained dentures
Number of subjects: 181
Study 12166709 — intervention group
Group type: COMPARATOR
Intervention: Conical crown-retained dentures (CC)
Number of subjects: 181
Study 12166709 — intervention group
Group type: COMPARATOR
Intervention: Parallel-sided retained dentures (PS)
Number of subjects: 181
Study 12166709 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair costs for clasp-retained dentures
Number of subjects: 181
Study 12166709 — intervention group
Group type: COMPARATOR
Intervention: Repair costs for double crown systems
Number of subjects: 181
Study 10597783 — intervention group
Group type: EXPERIMENTAL
Intervention: APV 1200 mg with 3TC/ZDV
Number of subjects: 84
Study 10597783 — intervention group
Group type: EXPERIMENTAL
Intervention: APV 900 mg with 3TC/ZDV
Number of subjects: 84
Study 10597783 — intervention group
Group type: COMPARATOR
Intervention: 3TC/ZDV with 1050 mg APV added at week 12
Number of subjects: 84
Study 10597783 — intervention group
Group type: EXPERIMENTAL
Intervention: APV 1050 mg with 3TC/ZDV
Number of subjects: 84
Study 8521562 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 30
Study 8521562 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg CR
Number of subjects: 30
Study 1958433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 23
Study 1958433 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 23
Study 31094251 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% velocity loss threshold
Number of subjects: 16
Study 31094251 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% velocity loss threshold
Number of subjects: 16
Study 31094251 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% velocity loss threshold
Number of subjects: 16
Study 30826975 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network descriptive sexual norms and behaviors
Number of subjects: 232
Study 30826975 — intervention group
Group type: EXPERIMENTAL
Intervention: Egos' norms of condomless sex with primary partners
Number of subjects: 232
Study 30826975 — intervention group
Group type: EXPERIMENTAL
Intervention: Egos' norms of condomless sex with casual partners
Number of subjects: 232
Study 30826975 — intervention group
Group type: EXPERIMENTAL
Intervention: Egos' norms of giving money/drugs for sex
Number of subjects: 232
Study 30826975 — intervention group
Group type: EXPERIMENTAL
Intervention: Egos' norms of receiving money/drugs for sex
Number of subjects: 232
Study 28522204 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN plus adefovir 10 mg/day
Number of subjects: 151
Study 28522204 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN plus tenofovir 245 mg/day
Number of subjects: 151
Study 28522204 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 151
Study 25407377 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer leader use (networked condition)
Number of subjects: 525
Study 25407377 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 525
Study 24330215 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological staged interventions
Number of subjects: 64
Study 24330215 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 64
Study 21246176 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-enriched light (8000 K)
Number of subjects: 54
Study 21246176 — intervention group
Group type: COMPARATOR
Intervention: Warm light (4000 K)
Number of subjects: 54
Study 19177141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild regimen (10-30 g per day of clobetasol propionate cream, tapering over 4 months)
Number of subjects: 312
Study 19177141 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (40 g per day of clobetasol propionate cream, tapering over 12 months)
Number of subjects: 312
Study 19177141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild regimen
Number of subjects: 312
Study 19177141 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 312
Study 17325296 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw garlic
Number of subjects: 192
Study 17325296 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered garlic supplement
Number of subjects: 192
Study 17325296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract supplement
Number of subjects: 192
Study 17325296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 14968388 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior VentroFix instrumentation
Number of subjects: 22
Study 14968388 — intervention group
Group type: COMPARATOR
Intervention: Posterior Universal Spine System stabilization
Number of subjects: 22
Study 11788172 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic tablet (Garlet) 800mg/day
Number of subjects: 100
Study 11788172 — intervention group
Group type: COMPARATOR
Intervention: Placebo 800mg/day
Number of subjects: 100
Study 9547667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group treatment program (CT)
Number of subjects: 62
Study 9547667 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy weight loss program (BT)
Number of subjects: 62
Study 9547667 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 62
Study 7979426 — intervention group
Group type: COMPARATOR
Intervention: TAE group (transcatheter arterial embolization)
Number of subjects: 75
Study 7979426 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE-RV group (arterial infusion chemotherapy through implantable port after TAE)
Number of subjects: 75
Study 7979426 — intervention group
Group type: COMPARATOR
Intervention: One-shot group (one-shot arterial infusion chemotherapy)
Number of subjects: 75
Study 7979426 — intervention group
Group type: EXPERIMENTAL
Intervention: RV group (arterial infusion chemotherapy through implantable port)
Number of subjects: 75
Study 7979426 — intervention group
Group type: EXPERIMENTAL
Intervention: RV group
Number of subjects: 75
Study 3052974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone acetate
Number of subjects: 127
Study 3052974 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 127
Study 31342902 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language, culturally adapted, individually tailored, internet-based PA intervention
Number of subjects: 205
Study 31342902 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting features
Number of subjects: 205
Study 31342902 — intervention group
Group type: EXPERIMENTAL
Intervention: PA tips
Number of subjects: 205
Study 31342902 — intervention group
Group type: EXPERIMENTAL
Intervention: PA reports
Number of subjects: 205
Study 31342902 — intervention group
Group type: COMPARATOR
Intervention: Spanish language, internet-based, Wellness Contact Control
Number of subjects: 205
Study 28699561 — intervention group
Group type: EXPERIMENTAL
Intervention: Camino Verde intervention using the SEPA approach
Number of subjects: 0
Study 28699561 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26405092 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalotuzumab 10mg/kg weekly (arm A)
Number of subjects: 344
Study 26405092 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalotuzumab 7.5mg/kg every alternate week (arm B)
Number of subjects: 344
Study 26405092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arm C)
Number of subjects: 344
Study 26405092 — intervention group
Group type: EXPERIMENTAL
Intervention: High IGF-1 mRNA tumors in arm A
Number of subjects: 344
Study 26405092 — intervention group
Group type: COMPARATOR
Intervention: High IGF-1 mRNA tumors in arm C
Number of subjects: 344
Study 23138388 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-breathing CCTA
Number of subjects: 74
Study 23138388 — intervention group
Group type: COMPARATOR
Intervention: Standard breath-holding CCTA
Number of subjects: 74
Study 21205942 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple stenting (provisional T-stenting)
Number of subjects: 913
Study 21205942 — intervention group
Group type: COMPARATOR
Intervention: Complex stenting techniques (crush, culotte, T-stenting)
Number of subjects: 913
Study 21205942 — intervention group
Group type: COMPARATOR
Intervention: Complex stenting techniques
Number of subjects: 913
Study 18447941 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day of sugar cane policosanols (SCP)
Number of subjects: 21
Study 18447941 — intervention group
Group type: COMPARATOR
Intervention: Placebo incorporated in margarine
Number of subjects: 21
Study 17192538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine (lapatinib at a dose of 1250 mg per day continuously plus capecitabine at a dose of 2000 mg per square meter on days 1 through 14 of a 21-day cycle)
Number of subjects: 0
Study 17192538 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (at a dose of 2500 mg per square meter on days 1 through 14 of a 21-day cycle)
Number of subjects: 0
Study 14529983 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy (group II)
Number of subjects: 60
Study 14529983 — intervention group
Group type: COMPARATOR
Intervention: Standard posterolateral thoracotomy (group I)
Number of subjects: 60
Study 10914847 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg hydroxychloroquine sulfate daily (Group A)
Number of subjects: 23
Study 10914847 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg hydroxychloroquine sulfate daily (Group B)
Number of subjects: 23
Study 10914847 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23
Study 8980924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 50 mg of amitriptyline (AT) daily for 6 weeks
Number of subjects: 15
Study 8980924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 25 mg of amitriptyline (AT) daily for 6 weeks
Number of subjects: 15
Study 1419760 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath-water-delivered 8-methoxypsoralen (bath 8-MOP)
Number of subjects: 44
Study 1419760 — intervention group
Group type: COMPARATOR
Intervention: Oral 8-methoxypsoralen (oral 8-MOP)
Number of subjects: 44
Study 3917496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamin 7%
Number of subjects: 0
Study 3917496 — intervention group
Group type: COMPARATOR
Intervention: Travasol 10% blend B
Number of subjects: 0
Study 31177055 — intervention group
Group type: EXPERIMENTAL
Intervention: Human donor milk
Number of subjects: 29
Study 31177055 — intervention group
Group type: COMPARATOR
Intervention: Formula milk
Number of subjects: 29
Study 31177055 — intervention group
Group type: EXPERIMENTAL
Intervention: Human donor milk with >60 kcal/100 mL
Number of subjects: 29
Study 29512041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 54
Study 29512041 — intervention group
Group type: COMPARATOR
Intervention: Light physical exercise
Number of subjects: 54
Study 26343171 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led self-efficacy-enhanced wheelchair training program (WheelSee)
Number of subjects: 28
Study 26343171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 24293632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus, followed by continuous infusion of 100 mg/h for patients >70 kg or 70 mg/h for patients <70 kg over 48 h)
Number of subjects: 14
Study 24293632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 22520119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV)
Number of subjects: 2036
Study 22520119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2036
Study 20212196 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 1636
Study 20212196 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1636
Study 17010979 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 75
Study 17010979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 16228196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (bolus of 0.23 mg/kg and infusion of 0.65 mg/kg)
Number of subjects: 10
Study 16228196 — intervention group
Group type: COMPARATOR
Intervention: Placebo normal saline
Number of subjects: 10
Study 12167390 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 343
Study 12167390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 9802525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g/kg)
Number of subjects: 50
Study 9802525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7639806 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 monoclonal antibody (MAb) cM‐T412
Number of subjects: 60
Study 7639806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2707917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg, three times a day)
Number of subjects: 58
Study 2707917 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (control group)
Number of subjects: 58
Study 357303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium ion‐specific electrode system for blood urea nitrogen analysis
Number of subjects: 187
Study 357303 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of urea in dialysate fluid
Number of subjects: 187
Study 30669717 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinghuaweikang capsules (160 mg, three times a day) + Quadruple therapy (esomeprazole 20 mg, twice a day; pectin bismuth 200 mg, three times a day; amoxicillin 1000 mg, twice a day; clarithromycin 500 mg, twice a day)
Number of subjects: 455
Study 30669717 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinghuaweikang capsules (160 mg, three times a day) + Quadruple therapy (esomeprazole 20 mg, twice a day; bismuth pectin 200 mg, three times a day; amoxicillin 1000 mg, twice a day; furazolidone 100 mg, twice a day)
Number of subjects: 455
Study 30669717 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy (esomeprazole 20 mg, twice a day; pectin bismuth 200 mg, three times a day; amoxicillin 1000 mg, twice a day; clarithromycin 500 mg, twice a day)
Number of subjects: 455
Study 30669717 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy (esomeprazole 20 mg, twice a day; bismuth pectin 200 mg, three times a day; amoxicillin 1000 mg, twice a day; furazolidone 100 mg, twice a day)
Number of subjects: 455
Study 29596646 — intervention group
Group type: EXPERIMENTAL
Intervention: OBMT therapy (bismuth, metronidazole, tetracycline with omeprazole)
Number of subjects: 384
Study 29596646 — intervention group
Group type: COMPARATOR
Intervention: OBAC therapy (bismuth, omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 384
Study 29596646 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OBMT and OBAC therapies
Number of subjects: 384
Study 26498268 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (CBT) for 11 weeks
Number of subjects: 133
Study 26498268 — intervention group
Group type: COMPARATOR
Intervention: Discussion group (active control)
Number of subjects: 133
Study 25321869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement (CTDR)
Number of subjects: 330
Study 25321869 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 330
Study 25321869 — intervention group
Group type: COMPARATOR
Intervention: Cervical total disc replacement (CTDR) compared with ACDF
Number of subjects: 330
Study 23262475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 1.5 g of magnesium sulphate followed by an infusion of 12 g in 24 h
Number of subjects: 216
Study 23262475 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered according to the same schedule as the treatment group
Number of subjects: 216
Study 21055665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 10 months
Number of subjects: 27
Study 21055665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21055665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 27
Study 17592101 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion control plate for 6 months
Number of subjects: 130
Study 17592101 — intervention group
Group type: COMPARATOR
Intervention: Usual care (dietary teaching)
Number of subjects: 130
Study 16302041 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (AQ+AS)
Number of subjects: 180
Study 16302041 — intervention group
Group type: EXPERIMENTAL
Intervention: Coartemether (Artemether-Lumefantrine)
Number of subjects: 180
Study 16302041 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulfadoxine-Pyrimethamine (AQ+SP)
Number of subjects: 180
Study 16302041 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine Monotherapy (AQ)
Number of subjects: 180
Study 12476475 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 80
Study 12476475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 80
Study 12476475 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 80
Study 12476475 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 80
Study 10190651 — intervention group
Group type: COMPARATOR
Intervention: Normotensives
Number of subjects: 289
Study 7672026 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg s.c.)
Number of subjects: 0
Study 7672026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2369230 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute plasmapheresis with hemofiltration
Number of subjects: 60
Study 2369230 — intervention group
Group type: COMPARATOR
Intervention: Acute plasmapheresis with Cell Saver
Number of subjects: 60
Study 2369230 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Number of subjects: 60
Study 2369230 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-poor plasma
Number of subjects: 60
Study 7218312 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical librarian service
Number of subjects: 8
Study 7218312 — intervention group
Group type: COMPARATOR
Intervention: Control settings
Number of subjects: 8
Study 31468714 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 µg
Number of subjects: 0
Study 31468714 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 700 µg
Number of subjects: 0
Study 31468714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31468714 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (open-label)
Number of subjects: 0
Study 30668840 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (Glu calculated at 2.68%)
Number of subjects: 240
Study 30668840 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamic acid inclusion levels: 2.88%
Number of subjects: 240
Study 30668840 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamic acid inclusion levels: 3.08%
Number of subjects: 240
Study 30668840 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamic acid inclusion levels: 3.28%
Number of subjects: 240
Study 30668840 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamic acid inclusion levels: 3.48%
Number of subjects: 240
Study 30668840 — intervention group
Group type: COMPARATOR
Intervention: L-glutamic acid inclusion levels: 2.68%
Number of subjects: 240
Study 28121892 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforator-based interposition flaps
Number of subjects: 30
Study 28121892 — intervention group
Group type: COMPARATOR
Intervention: Full-thickness skin grafts
Number of subjects: 30